Company Overview of Organovo Holdings, Inc.
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-...
6275 Nancy Ridge Drive
San Diego, CA 92121
Founded in 2007
Key Executives for Organovo Holdings, Inc.
Total Annual Compensation: $362.9K
Chief Financial Officer
Total Annual Compensation: $289.1K
Chief Strategy Officer
Total Annual Compensation: $289.8K
Chief Technology Officer and Executive Vice President of Research & Development
Total Annual Compensation: $289.1K
Executive Vice President of Commercial Operations
Total Annual Compensation: $268.5K
Compensation as of Fiscal Year 2014.
Organovo Holdings, Inc. Key Developments
Organovo Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2014
Aug 12 14
Organovo Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company's total revenues were $0.1 million compared with $0.11 million a year ago. Loss from operations was $6.4 million compared with $3.7 million a year ago. Net loss was $6.4 million or $0.08 per basic and diluted share compared with $3.77 million or $0.06 per basic and diluted share a year ago. Net cash used by operating activities for the three months ended June 30, 2014 was approximately $3.4 million as compared to $2.7 million used in operating activities for the three months ended June 30, 2013. This $0.7 million increase in cash usage can be attributed to a $2.7 million increase in operating expenses, partially offset by an overall increase of $0.7 million of non-cash expenses included in operations, including share-based compensation, depreciation and amortization, and a decrease in working capital.
Organovo Announces Appointment of Gregory T. Lucier as Corporate Advisor
Aug 6 14
Organovo Holdings, Inc. announced that Gregory T. Lucier has been appointed as a corporate advisor. In the role, Mr. Lucier will advise Chief Executive Officer Keith Murphy and the executive management team on various corporate issues. Mr. Lucier was formerly Chairman and CEO of Life Technologies. Prior to his tenure at Life Technologies, Mr. Lucier was a corporate officer of General Electric Company.
Organovo Holdings, Inc., Annual General Meeting, Aug 20, 2014
Jul 11 14
Organovo Holdings, Inc., Annual General Meeting, Aug 20, 2014., at 09:00 Pacific Daylight. Location: 6275 Nancy Ridge Dr.. Agenda: To consider the election of Robert Baltera, Jr. and James Glover as Class III Directors Nominees; to ratify the appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm for the fiscal year ending March 31, 2015; to hold a non-binding advisory vote on the compensation of named executive officers; and to transact such other business as may properly be brought before the meeting or any adjournment or postponement thereof.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|